Streetbeat News

Regulatory

ARDX

Ardelyx, Inc. (NASDAQ:ARDX) has shared preliminary data on the use of IBSRELA (tenapanor) in pediatric patients at the 2023 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting. The data, while preliminary and blinded to treatment assignment, is an important step towards assessing the safety and efficacy of IBSRELA among pediatric populations. The company is currently conducting a Phase 3 trial to assess the safety, tolerability, and efficacy of tenapanor in patients ages 12 to 17 with IBS-C.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 12:05 pm

DXR

Daxor Corporation (NASDAQ:DXR), a leader in blood volume measurement technology, has been accepted into the National Institutes of Health (NIH) Catalyze Preclinical Services Program. This program supports preclinical development, including studies and activities needed to meet regulatory requirements for therapeutic and device submissions. The effort will be done in collaboration with two nationally recognized contract research organizations, to support the continued development of Daxor's non-nuclear fluorescent blood volume analyzer (BVA) device.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 12:04 pm

BTCUSD

Cameron and Tyler Winklevoss, founders of cryptocurrency exchange Gemini, filed for a Bitcoin ETF in 2013, which was rejected by the SEC. Since then, the value of Bitcoin has increased by over 300 times. The SEC has postponed decisions on several Bitcoin ETF proposals, including those from BlackRock and Valkyrie. If one had invested $100 in Bitcoin in 2013, they would now have a profit of $30,500.

Portfolio Pulse from Mehab Qureshi

October 04, 2023 | 12:03 pm

MYMD

MyMD Pharmaceuticals is planning to share information about the company and its product pipeline, including an update on recent Phase 2 study results for MYMD-1 in Sarcopenia, at the upcoming Biofuture 2023 meeting.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:48 am

AAPL

Apple Inc. (NASDAQ:AAPL) has been accused by the Institute of Public and Environmental Affairs (IPE), a Chinese environmental research organization, of 'climate-washing' in relation to its claim that the new Apple Watch is 'carbon neutral'. Apple defended its claim, stating that the carbon neutrality of the Apple Watch series was independently validated by SCS Global Services. However, IPE's report argued that Apple's supplier transparency was lacking and criticized its heavy reliance on buying renewable energy certificates.

Portfolio Pulse from Benzinga Neuro

October 04, 2023 | 11:48 am

BTCUSD

Kevin O'Leary, entrepreneur and TV personality, predicts the end of the 'crypto cowboys' era as the cryptocurrency industry moves towards regulation. He believes that the founders of the crypto industry will soon face regulatory challenges and that he would only get involved in an exchange if it adheres to 100% compliance standards. O'Leary also emphasized the need for a regulatory framework that supports institutional investment and tackles fraudulent activities within the crypto space.

Portfolio Pulse from Mehab Qureshi

October 04, 2023 | 11:33 am

AMZN

Amazon.com Inc (NASDAQ:AMZN) is reportedly preparing to enter India's satellite communications industry, potentially competing with Elon Musk's Starlink. The company is said to be close to seeking a satellite communications service operator's license for its Project Kuiper. This move would allow Amazon to offer satellite-based internet services in sectors such as maritime and aviation. Other competitors in this space include Starlink, OneWeb, and Jio Satellite Communications.

Portfolio Pulse from Shomik Sen Bhattacharjee

October 04, 2023 | 11:17 am

MRNA

Moderna has announced Phase 1/2 data from mRNA-1083, a combination vaccine against Influenza and COVID-19. The results show strong immunogenicity and an acceptable reactogenicity and safety profile compared to standalone vaccines.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:11 am

PYPD

PolyPid Ltd. (NASDAQ:PYPD) has published positive preclinical results demonstrating the safety profile of D-PLEX100 and the PLEX technology platform in juvenile animals. The safety and toxicokinetics of D-PLEX100 were tested in juvenile swine for a period of nine months with no treatment-related adverse events observed. PolyPid's ongoing Phase 3 SHIELD II trial of D-PLEX100 for the prevention of surgical site infections is currently recruiting patients.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:09 am

PRTC

PureTech Health's founded entity, Vedanta Biosciences, has dosed the first patient in a Phase 2 clinical trial of VE202 for the treatment of ulcerative colitis. The U.S. FDA has granted Fast Track designation to VE202, which is designed to expedite the review of drugs that treat serious conditions and fill an unmet medical need.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 11:06 am